WO2002081496A3 - Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores - Google Patents

Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores Download PDF

Info

Publication number
WO2002081496A3
WO2002081496A3 PCT/CU2002/000003 CU0200003W WO02081496A3 WO 2002081496 A3 WO2002081496 A3 WO 2002081496A3 CU 0200003 W CU0200003 W CU 0200003W WO 02081496 A3 WO02081496 A3 WO 02081496A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
tumours
diagnosis
murine
frs
Prior art date
Application number
PCT/CU2002/000003
Other languages
English (en)
French (fr)
Other versions
WO2002081496A2 (es
Inventor
De Acosta Del Rio Cristi Mateo
Valladares Josefa Lombardero
Navarro Lourdes Tatiana Roque
Requena Alejandro Lopez
Original Assignee
Centro Inmunologia Molecular
De Acosta Del Rio Cristi Mateo
Valladares Josefa Lombardero
Navarro Lourdes Tatiana Roque
Requena Alejandro Lopez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0208676A priority Critical patent/BR0208676B1/pt
Priority to KR1020037012969A priority patent/KR100946168B1/ko
Priority to JP2002579482A priority patent/JP2004528033A/ja
Priority to EP02759752A priority patent/EP1411064B1/en
Priority to DK02759752T priority patent/DK1411064T3/da
Priority to NZ528599A priority patent/NZ528599A/en
Priority to HU0401695A priority patent/HU228105B1/hu
Priority to SI200230660T priority patent/SI1411064T1/sl
Priority to US10/473,977 priority patent/US20040253233A1/en
Priority to MXPA03008739A priority patent/MXPA03008739A/es
Priority to DE60223547T priority patent/DE60223547T2/de
Priority to EA200301098A priority patent/EA006310B1/ru
Application filed by Centro Inmunologia Molecular, De Acosta Del Rio Cristi Mateo, Valladares Josefa Lombardero, Navarro Lourdes Tatiana Roque, Requena Alejandro Lopez filed Critical Centro Inmunologia Molecular
Priority to AU2002308348A priority patent/AU2002308348B2/en
Priority to CA2441845A priority patent/CA2441845C/en
Priority to SK1226-2003A priority patent/SK287914B6/sk
Priority to UA2003108989A priority patent/UA75393C2/uk
Publication of WO2002081496A2 publication Critical patent/WO2002081496A2/es
Priority to IS6965A priority patent/IS6965A/is
Priority to BG108228A priority patent/BG66304B1/bg
Priority to NO20034437A priority patent/NO20034437L/no
Priority to HR20030805A priority patent/HRP20030805B1/xx
Publication of WO2002081496A3 publication Critical patent/WO2002081496A3/es
Priority to HK05102752A priority patent/HK1070080A1/xx
Priority to AU2007231687A priority patent/AU2007231687B2/en
Priority to US12/407,046 priority patent/US8758753B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con la obtención de anticuerpos modificados por ingeniería genética a partir del anticuerpo monoclonal murino P3 (AcM P3), producido por el hibridoma depositado según el tratado de Budapest bajo el número ECACC 94113026 y de su anti-idiotipo 1E10 (AcMai 1E10) producido por el hibridoma ECACC 97112901, con el objetivo de lograr anticuerpos con las mismas propiedades de reconocimiento de los originales pero que sean menos inmunogénicos que éstos. Los anticuerpos quiméricos, contienen los dominios variables de la inmunoglobulina murina y las regiones constantes de la inmunoglobulina humana; y los humanizados, además de contener las regiones constantes de la inmunoglobulina humana, son modificados en la región de los marcos (FRs) murinos y en particular en aquellas zonas que pudieran resultar en un sitio antigénico para las células T, por lo que algunas posiciones de los FRS son humanas. Estos anticuerpos pueden ser utilizados en el diagnóstico y la terapia de diferentes tipos de tumores.
PCT/CU2002/000003 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores WO2002081496A2 (es)

Priority Applications (23)

Application Number Priority Date Filing Date Title
AU2002308348A AU2002308348B2 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
KR1020037012969A KR100946168B1 (ko) 2001-04-06 2002-04-08 강글리오사이드-관련 재조합 항체 및 종양의 진단 및치료에 있어서 이의 용도
CA2441845A CA2441845C (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
DK02759752T DK1411064T3 (da) 2001-04-06 2002-04-08 Gangliosid-associerede rekombinante antistoffer og anvendelsen deraf i diagnosen og behandlingen af tumorer
NZ528599A NZ528599A (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
HU0401695A HU228105B1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
SI200230660T SI1411064T1 (sl) 2001-04-06 2002-04-08 Rekombinantna protitelesa v povezavi z gangliozidi in njihova uporaba pri diagnozi in zdravljenju tumorjev
US10/473,977 US20040253233A1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
MXPA03008739A MXPA03008739A (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliosidos. su uso en el diagnostico y tratamiento de tumores.
DE60223547T DE60223547T2 (de) 2001-04-06 2002-04-08 Gangliosid-assoziierte rekombinante antikörper und deren verwendung bei der diagnose und behandlung von tumoren
EA200301098A EA006310B1 (ru) 2001-04-06 2002-04-08 Ассоциированные с ганглиозидами рекомбинантные антитела и их применение в диагностике и лечении опухолей
BRPI0208676A BR0208676B1 (pt) 2001-04-06 2002-04-08 Chemical monoclonal antibody, pharmaceutical composition, and, use of a monoclonal antibody
JP2002579482A JP2004528033A (ja) 2001-04-06 2002-04-08 ガングリオシド関連組換え抗体及び腫瘍の診断及び治療への使用
EP02759752A EP1411064B1 (en) 2001-04-06 2002-04-08 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
SK1226-2003A SK287914B6 (sk) 2001-04-06 2002-04-08 Chimeric monoclonal antibody and its use in the preparation of medicament for the treatment of malignant tumors, cell line and pharmaceutical composition
UA2003108989A UA75393C2 (en) 2001-04-06 2002-08-04 Chimeric monoclonal antibody, identifying gangliosides containing n-glycolyl sialic acid, cells line producing it and pharmaceutical compositions containing it
IS6965A IS6965A (is) 2001-04-06 2003-09-23 Ganglíósíð-tengd raðbrigða mótefni og notkun þeirra í sjúkdómsgreiningu og meðferð á æxlum
BG108228A BG66304B1 (bg) 2001-04-06 2003-10-03 Рекомбинантни антитела, свързващи ганглиозид и тяхното използване при диагностициране и лечение на тумори
NO20034437A NO20034437L (no) 2001-04-06 2003-10-03 Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
HR20030805A HRP20030805B1 (en) 2001-04-06 2003-10-06 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
HK05102752A HK1070080A1 (en) 2001-04-06 2005-04-01 Ganglioside-associated recombinant antibodies and the use thereof in the preparation of medicament for the diagnosis and treatment of tumors
AU2007231687A AU2007231687B2 (en) 2001-04-06 2007-10-26 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
US12/407,046 US8758753B2 (en) 2001-04-06 2009-03-19 Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU84/2001 2001-04-06
CU2001008420010084A CU23007A1 (es) 2001-04-06 2001-04-06 Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10473977 A-371-Of-International 2002-04-08
US12/407,046 Division US8758753B2 (en) 2001-04-06 2009-03-19 Ganglioside associated recombinant antibodies and the use thereof in the treatment of tumors

Publications (2)

Publication Number Publication Date
WO2002081496A2 WO2002081496A2 (es) 2002-10-17
WO2002081496A3 true WO2002081496A3 (es) 2004-02-19

Family

ID=40291118

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CU2002/000003 WO2002081496A2 (es) 2001-04-06 2002-04-08 Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores
PCT/CU2002/000002 WO2002081661A2 (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CU2002/000002 WO2002081661A2 (es) 2001-04-06 2002-04-08 Combinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos

Country Status (37)

Country Link
US (3) US20050069535A1 (es)
EP (3) EP1798243B1 (es)
JP (2) JP4366080B2 (es)
KR (3) KR100863509B1 (es)
CN (3) CN101054417B (es)
AR (2) AR033123A1 (es)
AT (3) ATE477279T1 (es)
AU (3) AU2002308348B2 (es)
BG (2) BG66293B1 (es)
BR (3) BR0208675A (es)
CA (2) CA2443372C (es)
CU (1) CU23007A1 (es)
CZ (2) CZ304424B6 (es)
DE (2) DE60228561D1 (es)
DK (2) DK1384726T3 (es)
EA (2) EA006936B1 (es)
EC (2) ECSP034788A (es)
ES (2) ES2296986T3 (es)
HK (3) HK1066818A1 (es)
HR (2) HRP20030805B1 (es)
HU (2) HU228106B1 (es)
IL (2) IL158246A0 (es)
IS (2) IS2701B (es)
MX (2) MXPA03008738A (es)
MY (3) MY145703A (es)
NO (2) NO331533B1 (es)
NZ (2) NZ528599A (es)
PE (1) PE20020972A1 (es)
PL (2) PL371770A1 (es)
PT (2) PT1384726E (es)
SG (1) SG161737A1 (es)
SI (2) SI1384726T1 (es)
SK (2) SK287783B6 (es)
UA (3) UA75393C2 (es)
UY (2) UY27243A1 (es)
WO (2) WO2002081496A2 (es)
ZA (2) ZA200307585B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
RU2396088C2 (ru) * 2005-02-04 2010-08-10 СУРВАК АпС Вакцина на основе пептидов сурвивина
FI20055398A0 (fi) * 2005-07-08 2005-07-08 Suomen Punainen Risti Veripalv Menetelmä solupopulaatioiden evaluoimiseksi
CA2618796C (en) * 2005-08-11 2018-01-02 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmune disease
WO2007024535A2 (en) 2005-08-19 2007-03-01 Wyeth Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
TWI434855B (zh) 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途
US20110286937A1 (en) * 2008-02-22 2011-11-24 Gifu University Synthetic glycolipid-containing liposome
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
NZ612647A (en) 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
JP6132548B2 (ja) * 2009-04-01 2017-05-24 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５抗体および免疫接合体および使用方法
CU23736A1 (es) 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011026242A1 (en) * 2009-09-03 2011-03-10 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
AU2012205663B2 (en) * 2011-01-10 2017-02-02 Emory University Antibodies directed against influenza
CU24070B1 (es) 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
EP2641916A1 (en) * 2012-03-23 2013-09-25 Centre National de la Recherche Scientifique (C.N.R.S) Novel antibodies anti-sPLA2-IIA and uses thereof
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
PE20210107A1 (es) 2013-12-17 2021-01-19 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
JP2017512759A (ja) * 2014-04-10 2017-05-25 オービーアイ ファーマ インコーポレイテッド 抗体、前記抗体を産生するハイブリドーマ、前記抗体を含む薬学的組成物及びその用途
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
IL256079B2 (en) 2015-06-16 2024-01-01 Genentech Inc Human antibodies with improved affinity to FCRH5 - and methods of use
WO2018017864A2 (en) * 2016-07-20 2018-01-25 Oncomed Pharmaceuticals, Inc. Pvrig-binding agents and uses thereof
RU2765410C2 (ru) 2016-11-30 2022-01-28 Онкомед Фармасьютикалс, Инк. Способы лечения рака, включающие связывающие tigit агенты
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0657471A1 (en) * 1993-12-09 1995-06-14 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
EP0699755A2 (en) * 1994-06-30 1996-03-06 Centro de Inmunologia Molecular Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them
US5589573A (en) * 1993-10-06 1996-12-31 Yoshihide Hagiwara Amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences
US6207815B1 (en) * 1988-10-19 2001-03-27 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2754206B2 (ja) * 1987-11-17 1998-05-20 メクト株式会社 α２→３結合を認識するモノクローナル抗体
DE69327620T2 (de) * 1992-08-18 2000-08-03 Immunologia Molecular Ciudad D Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6063379A (en) * 1993-12-09 2000-05-16 Centro De Inmunologia Molecular Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207815B1 (en) * 1988-10-19 2001-03-27 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
US5589573A (en) * 1993-10-06 1996-12-31 Yoshihide Hagiwara Amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences
EP0657471A1 (en) * 1993-12-09 1995-06-14 Centro de Inmunologia Molecular Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
EP0699755A2 (en) * 1994-06-30 1996-03-06 Centro de Inmunologia Molecular Method for obtaining modified immunoglobulins with reduced immunogenicity of murine antibody variable domains, compositions containing them

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GEORGE P. SMITH: "Sequence of the full-lenght immunoglobulin kappa-chain of mouse myeloma MPC 11.", BIOCHEMISTRY JOURNAL, vol. 171, no. 2, 1978, pages 337 - 347, XP002902758 *
HUANG D.-B. ET AL: "Comparison of crystal structures of two homologous proteins: Structural origin of altered domain interactions in immunoglobulin light-chain dimers.", BIOCHEMISTRY, vol. 33, no. 49, 1994, pages 14848 - 14857, XP002902756 *
KAVALER J ET AL: "A set of closely related antibodies dominates the primary antibody response to the antigenic site CB of the A/PR/8/34 influenza virus hemagglutinin.", THE JOURNAL OF IMMUNOLOGY, vol. 145, no. 7, 1 October 1990 (1990-10-01), pages 2312 - 2321, XP002902757, ISSN: 0022-1767 *
PEREZ A ET AL: "Immunogenetic analysis of variable regions encoding AB1 and gamma-Type AB2 antibodies from the NeuGc-containing ganglioside family.", HYBRIDOMA, vol. 20, no. 4, 2001, pages 211 - 221, XP002902755 *

Also Published As

Publication number Publication date
CN100349920C (zh) 2007-11-21
HUP0401355A3 (en) 2012-05-29
AU2002308347B2 (en) 2006-09-14
ATE378356T1 (de) 2007-11-15
ZA200307679B (en) 2005-03-30
CZ20032641A3 (cs) 2004-07-14
PL371770A1 (en) 2005-06-27
MXPA03008738A (es) 2003-12-11
CA2441845C (en) 2011-06-07
ES2312610T3 (es) 2009-03-01
JP2004525953A (ja) 2004-08-26
IL158246A0 (en) 2004-05-12
EA006936B1 (ru) 2006-06-30
CA2443372A1 (en) 2002-10-17
IL158246A (en) 2010-05-31
HK1109160A1 (en) 2008-05-30
AR033123A1 (es) 2003-12-03
AU2002308348B2 (en) 2007-11-22
CU23007A1 (es) 2004-12-17
IS2701B (is) 2010-11-15
BR0208675A (pt) 2004-08-03
EP1384726B1 (en) 2008-08-27
BR0208676B1 (pt) 2017-11-14
ATE406386T1 (de) 2008-09-15
NO20034436L (no) 2003-12-02
US8758753B2 (en) 2014-06-24
UY27243A1 (es) 2002-09-30
BG66293B1 (en) 2013-02-28
NO20034437D0 (no) 2003-10-03
EP1384726A2 (en) 2004-01-28
MY137078A (en) 2008-12-31
HRP20030805A2 (en) 2005-08-31
CA2443372C (en) 2013-05-28
HRP20030806A2 (en) 2005-08-31
NO331533B1 (no) 2012-01-23
SI1384726T1 (sl) 2009-04-30
KR20030087053A (ko) 2003-11-12
WO2002081661A2 (es) 2002-10-17
HK1066818A1 (es) 2005-04-01
PE20020972A1 (es) 2003-01-02
SK12262003A3 (sk) 2004-08-03
UA76745C2 (uk) 2006-09-15
EA200301098A1 (ru) 2004-04-29
PT1411064E (pt) 2008-02-12
US20100297008A1 (en) 2010-11-25
ECSP034787A (es) 2004-01-28
EP1411064B1 (en) 2007-11-14
ATE477279T1 (de) 2010-08-15
KR20080080680A (ko) 2008-09-04
KR100863509B1 (ko) 2008-10-15
HK1070080A1 (en) 2005-06-10
DK1384726T3 (da) 2008-12-15
ES2296986T3 (es) 2008-05-01
PL371937A1 (en) 2005-07-11
SK287914B6 (sk) 2012-03-02
CZ296276B6 (cs) 2006-02-15
BG66304B1 (bg) 2013-03-29
HU228105B1 (en) 2012-11-28
WO2002081496A2 (es) 2002-10-17
CN101054417A (zh) 2007-10-17
BG108227A (bg) 2005-04-30
PT1384726E (pt) 2008-12-05
MY157372A (en) 2016-06-15
IS6965A (is) 2003-09-23
EP1411064A2 (en) 2004-04-21
CA2441845A1 (en) 2002-10-17
BG108228A (bg) 2005-04-30
WO2002081661A3 (es) 2003-01-03
CZ20032668A3 (cs) 2004-07-14
HUP0401695A3 (en) 2012-05-29
CN1507452A (zh) 2004-06-23
SG161737A1 (en) 2010-06-29
HUP0401355A2 (hu) 2004-10-28
JP4366080B2 (ja) 2009-11-18
EA006310B1 (ru) 2005-10-27
AR033122A1 (es) 2003-12-03
NO20034437L (no) 2003-12-02
ECSP034788A (es) 2004-01-28
CN101054417B (zh) 2012-07-11
AU2007231687B2 (en) 2010-09-30
HRP20030806B1 (en) 2011-11-30
CN1535282A (zh) 2004-10-06
UY27242A1 (es) 2002-07-31
US20050069535A1 (en) 2005-03-31
HRP20030805B1 (en) 2011-11-30
EP1798243A2 (en) 2007-06-20
CN1319991C (zh) 2007-06-06
EP1798243A3 (en) 2007-10-17
NZ528598A (en) 2005-03-24
IS6964A (is) 2003-09-23
MY145703A (en) 2012-03-30
DE60228561D1 (de) 2008-10-09
KR20030092048A (ko) 2003-12-03
SI1411064T1 (sl) 2008-04-30
KR100919617B1 (ko) 2009-09-29
UA86768C2 (ru) 2009-05-25
EA200301097A1 (ru) 2004-02-26
CZ304424B6 (cs) 2014-04-30
SK287783B6 (sk) 2011-09-05
UA75393C2 (en) 2006-04-17
JP2004528033A (ja) 2004-09-16
NZ528599A (en) 2005-03-24
KR100946168B1 (ko) 2010-03-11
HUP0401695A2 (en) 2006-08-28
EP1798243B1 (en) 2010-08-11
NO20034436D0 (no) 2003-10-03
PL208109B1 (pl) 2011-03-31
ZA200307585B (en) 2004-09-16
HU228106B1 (en) 2012-11-28
DE60223547T2 (de) 2008-09-18
MXPA03008739A (es) 2003-12-11
AU2007231687A1 (en) 2007-11-22
DK1411064T3 (da) 2008-03-25
BRPI0208675B1 (pt) 2018-03-13
US20040253233A1 (en) 2004-12-16
DE60223547D1 (de) 2007-12-27
SK12162003A3 (sk) 2004-05-04
BR0208676A (pt) 2008-04-08

Similar Documents

Publication Publication Date Title
WO2002081496A3 (es) Anticuerpos recombinantes asociados a gangliósidos. su uso en el diagnóstico y tratamiento de tumores
IL135221A0 (en) Natural humanized antibody and methods for the preparation thereof
TW222279B (es)
RU96115107A (ru) "очеловеченные" антитела и их использование
Schultes et al. Anti-idiotype induction therapy: Anti-CA125 antibodies (Ab 3) mediated tumor killing in patients treated with Ovarex mAb B43. 13 (Ab 1)
EP0783313A4 (en) MONOCLONAL ANTIBODIES OF HUMAN MOUSE HUMAN ANTI-CEA, TYPE III GRAFTS IN THE DETERMINING REGION OF COMPLEMENTARITY (CDR)
HUP0101160A2 (hu) Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
WO1997022699A3 (en) Murine monoclonal anti-idiotype antibody 11d10 an methods of use thereof
ATE316137T1 (de) Humanisierte antikörper gegen den epidermalen wachstumsfaktorrezeptor
ATE512224T1 (de) Rekonstituierter menschlicher anti-hm.1 antikörper
EP1135477A4 (en) HUMANIZED MONOCLONAL ANTIBODIES
EP0784684B8 (en) RECOMBINANT PEPTIDES DERIVED FROM THE Mc3 ANTI-BA46 ANTIBODY, METHODS OF USE THEREOF, AND METHODS OF HUMANIZING ANTIBODY PEPTIDES
ES2015654A6 (es) Un procedimiento para preparar anticuerpos anti-idiotipicos para antigeno asociado con melanoma, de alto peso molecular anti-humano.
CR7091A (es) Anticuerpos recombinantes asociados a gangliosidos, su uso en el diagnóstico y tratameinto de tumores
Kusakabe et al. Accumulation enhancement of human monoclonal antibody HB4C5 to lung tumor xenografts by N-deglycosylation
Saito et al. Establishment of internal-image anti-idiotype monoclonal antibodies to a human antibody to lung cancer
KR930013103A (ko) 종양 관련의 모노클로날 항체 88bv59
HOURANIEH MONOCLONAL ANTIBODY WITH SPECIFICITY TO HUMAN XL-FIBRIN.
CY1107163T1 (el) Συνδεδεμενα με γαγγλιοζιτη ανασυνδυασμενα αντισωματα και η χρησιμοποιηση αυτων στη διαγνωση και θεραπευτικη αγωγη ογκων
IT1254705B (it) Anticorpi monoclonali specifici per il fattore neuronotrofico ciliare (cntf) umano ricombinante
RU96109830A (ru) Антиидиотипические антитела, которые индуцируют иммунный ответ против рецептора эпидермального фактора роста

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2441845

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008739

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1552/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003/07585

Country of ref document: ZA

Ref document number: 200307585

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 03086749A

Country of ref document: CO

Ref document number: 03086749

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: PV2003-2668

Country of ref document: CZ

Ref document number: 528599

Country of ref document: NZ

Ref document number: CR2003-007091

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 12262003

Country of ref document: SK

Ref document number: 1020037012969

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 10822802

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20030805A

Country of ref document: HR

Ref document number: 2002579482

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002759752

Country of ref document: EP

Ref document number: 028086309

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200301098

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2002308348

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 10473977

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002759752

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-2668

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 528599

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002759752

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002308348

Country of ref document: AU

Date of ref document: 20020408

Kind code of ref document: B

ENP Entry into the national phase

Ref document number: PI0208676

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 1020087019420

Country of ref document: KR